Together, these data support the idea that EZH2 negatively regulates FOXO3 transcription in BRCA1-deficient breast cancer cells, whereas this EZH2 activity is repressed by BRCA1 in BRCA1-competent cells. This evidence concerns the gene FOXO3 and breast carcinoma.